Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part I Clinical syndromes: general
- Part II Clinical syndromes: head and neck
- Part III Clinical syndromes: eye
- Part IV Clinical syndromes: skin and lymph nodes
- Part V Clinical syndromes: respiratory tract
- Part VI Clinical syndromes: heart and blood vessels
- Part VII Clinical syndromes: gastrointestinal tract, liver, and abdomen
- Part VIII Clinical syndromes: genitourinary tract
- Part IX Clinical syndromes: musculoskeletal system
- Part X Clinical syndromes: neurologic system
- Part XI The susceptible host
- 84 Evaluation of suspected immunodeficiency
- 85 Infections in the neutropenic patient
- 86 Infections in patients with neoplastic disease
- 87 Corticosteroids, cytotoxic agents, and infection
- 88 Biologics
- 89 Infections in transplant recipients
- 90 Diabetes and infection
- 91 Infectious complications in the injection and non-injection drug user
- 92 Infections in the alcoholic
- 93 Infections in the elderly
- 94 Neonatal infection
- 95 Pregnancy and the puerperium: infectious risks
- 96 Dialysis-related infection
- 97 Overwhelming postsplenectomy infection
- Part XII HIV
- Part XIII Nosocomial infection
- Part XIV Infections related to surgery and trauma
- Part XV Prevention of infection
- Part XVI Travel and recreation
- Part XVII Bioterrorism
- Part XVIII Specific organisms: bacteria
- Part XIX Specific organisms: spirochetes
- Part XX Specific organisms: Mycoplasma and Chlamydia
- Part XXI Specific organisms: Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific organisms: fungi
- Part XXIII Specific organisms: viruses
- Part XXIV Specific organisms: parasites
- Part XXV Antimicrobial therapy: general considerations
- Index
- References
86 - Infections in patients with neoplastic disease
from Part XI - The susceptible host
Published online by Cambridge University Press: 05 April 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part I Clinical syndromes: general
- Part II Clinical syndromes: head and neck
- Part III Clinical syndromes: eye
- Part IV Clinical syndromes: skin and lymph nodes
- Part V Clinical syndromes: respiratory tract
- Part VI Clinical syndromes: heart and blood vessels
- Part VII Clinical syndromes: gastrointestinal tract, liver, and abdomen
- Part VIII Clinical syndromes: genitourinary tract
- Part IX Clinical syndromes: musculoskeletal system
- Part X Clinical syndromes: neurologic system
- Part XI The susceptible host
- 84 Evaluation of suspected immunodeficiency
- 85 Infections in the neutropenic patient
- 86 Infections in patients with neoplastic disease
- 87 Corticosteroids, cytotoxic agents, and infection
- 88 Biologics
- 89 Infections in transplant recipients
- 90 Diabetes and infection
- 91 Infectious complications in the injection and non-injection drug user
- 92 Infections in the alcoholic
- 93 Infections in the elderly
- 94 Neonatal infection
- 95 Pregnancy and the puerperium: infectious risks
- 96 Dialysis-related infection
- 97 Overwhelming postsplenectomy infection
- Part XII HIV
- Part XIII Nosocomial infection
- Part XIV Infections related to surgery and trauma
- Part XV Prevention of infection
- Part XVI Travel and recreation
- Part XVII Bioterrorism
- Part XVIII Specific organisms: bacteria
- Part XIX Specific organisms: spirochetes
- Part XX Specific organisms: Mycoplasma and Chlamydia
- Part XXI Specific organisms: Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific organisms: fungi
- Part XXIII Specific organisms: viruses
- Part XXIV Specific organisms: parasites
- Part XXV Antimicrobial therapy: general considerations
- Index
- References
Summary
Patients with neoplastic disease and suspected infection require the following main factors to be considered in their evaluation: (1) geographic predisposition for exposure to and to acquire infection including prior colonization with drug-resistant organisms and alteration in hosts’ microbiota; (2) known and unrecognized immune defect or defects due to underlying malignancy or antineoplastic therapy, or both (Table 86.1); (3) breakthrough infections due to drug-resistant pathogens in patients receiving antimicrobial chemoprophylaxis, and (4) familial/genetic predisposition to certain infections in the immunocompromised host. The febrile cancer patient may also have fever from noninfectious conditions such as tumor fever or drug fever. After evaluation, the next question is whether to treat empirically.
EPIDEMIOLOGY
People may be exposed to a variety of organisms through travel, work, habits, or hobbies; in the home; or in other hospitals, outpatient clinics, and infusion centers. A person with children at home is likely to be exposed to a number of infectious agents such as influenza, parainfluenza, respiratory syncytial virus, varicella-zoster virus (VZV), human herpesvirus 6 (HHV-6), and cytomegalovirus (CMV). Hospitals are a rich source of antibiotic-resistant microorganisms, including multidrug-resistant Staphylococcus aureus (MRSA), vancomycin-resistant and/or vancomycin-tolerant Enterococcus species, multidrug-resistant Pseudomonas and Stenotrophomonas, and extended-spectrum β-lactamase producing Enterobacteriaceae such as Escherichia coli and Klebsiella species. The recent global spread of carbapenem-resistant Enterobacteriaceae (CRE) has underscored the limitations of antibiotic regimens.
- Type
- Chapter
- Information
- Clinical Infectious Disease , pp. 558 - 562Publisher: Cambridge University PressPrint publication year: 2015